Phase II Clinical Trial With Proteomic Profiling Of Imatinib Mesylate (Gleevec; STI571), A PDGFR And C-Kit Inhibitor, In Patients With Refractory Or Relapsed Epithelial Ovarian Cancer, Fallopian Tube And Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2011
At a glance
- Drugs Imatinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2007 Status change from in progress to completed.
- 30 Aug 2005 New trial record.